Georgetown University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Georgetown University sits in the top decile of US sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count).

227 total trials 34 currently recruiting 130 completed early-phase tilt top decile by trial count

Georgetown University: 227 sponsored US clinical trials, 34 recruiting.

Georgetown University sponsors 227 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 130 completed. 27 of these trials are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 5 trials.

Top-decile sponsor footprint

Georgetown University ranks in the top decile of sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 26/100

130 of 174 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

227 total, page 2 of 5

NOT YET RECRUITING Phase 2

MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer

NCT07644598
NOT YET RECRUITING NA

Expanding Genetic Access for Prostate Cancer Survivors

NCT07618520
NOT YET RECRUITING Phase 2

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

NCT07645326
COMPLETED Phase 4

Istradefylline Effect Protocol on Parkinson's Disease Tremor

NCT05885360
COMPLETED NA

Educating Providers About Lung Screening

NCT05064046
TERMINATED Phase 2

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

NCT04720664
COMPLETED Phase 3

Educating QUitline Callers About Lung Cancer Screening

NCT05046951
TERMINATED Phase 4

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

NCT04657679
COMPLETED Early Phase 1

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

NCT04814602
COMPLETED Early Phase 1

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea

NCT04414722
COMPLETED NA

Online Trial of Meditation and Behavior

NCT04632875
COMPLETED Phase 1

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

NCT04292743
COMPLETED Phase 2

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

NCT04306367
COMPLETED NA

Streamlined Genetic Testing in Prostate Cancer

NCT04359758
COMPLETED NA

Enhance the Use of Genetic Counseling and Testing in Latinas

NCT04544501
COMPLETED NA

Optimizing Hookah Tobacco Public Education Messages to Reduce Young Adult Use

NCT04252014
COMPLETED NA

A Mobile Text Messaging Intervention for Indoor Tanning Addiction

NCT04055272
COMPLETED Phase 1

Safety and Tolerability of Oral Proglumide for NASH

NCT04152473
COMPLETED NA

Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects

NCT04107207
COMPLETED Early Phase 1

Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics

NCT03755765
COMPLETED

Reducing Perioperative S. Aureus Transmission Via OR PathTrac

NCT04657185
COMPLETED Phase 1

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
COMPLETED Phase 2

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

NCT03888222
COMPLETED Phase 1

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

NCT03854903
COMPLETED Phase 4

Investigation of a Novel Wound Gel to Improve Wound Healing in Chronic Wounds

NCT03686904
TERMINATED Phase 2

Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

NCT03535506
COMPLETED NA

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

NCT02957981
COMPLETED NA

Metta Meditation Training on Prosocial Behavior

NCT03894930
COMPLETED NA

Optimizing Risk Messages for Waterpipe Tobacco Cessation in Young Adults

NCT03595280
TERMINATED Phase 1

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

NCT03376659
COMPLETED Phase 4

Treatments for Anxiety: Meditation and Escitalopram

NCT03522844
COMPLETED Phase 2

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

NCT03487666
TERMINATED Phase 2

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy

NCT03193437
COMPLETED NA

Stroke Transitions of Care to Reduce Hospital Length of Stay

NCT04434638
COMPLETED Phase 1

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03325816
TERMINATED Phase 1

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

NCT03209401
COMPLETED Phase 2

Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics

NCT03181516
TERMINATED Phase 2

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

NCT02978443
COMPLETED NA

Testing a Culturally Adapted Telephone Genetic Counseling Intervention

NCT03959267
COMPLETED NA

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

NCT03511690
COMPLETED NA

Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli

NCT03206437
COMPLETED NA

MEND 2: Making Treatment Decisions Using Genomic Testing

NCT03183050
COMPLETED Phase 3

The Lung Screening, Tobacco and Health Project

NCT03200236
COMPLETED Phase 1

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

NCT02956382
COMPLETED NA

ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2

NCT03029286
COMPLETED Phase 2

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

NCT02954978
COMPLETED Phase 2

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

NCT02947893
TERMINATED

The Effects of Opioid Taper on Opioid-Induced Hyperalgesia

NCT03063905
COMPLETED Phase 2

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

NCT02692755
TERMINATED NA

Envarsus XR in African American Renal Transplant Recipients

NCT02956005
← Previous Page 2 of 5 Next →

Phase Distribution

PhaseTrial count
Phase 1 43
Phase 2 55
Phase 3 16
Phase 4 11

Therapeutic Areas

Breast Cancer 5
Stroke 4
Agoraphobia 3
Hereditary Breast and Ovarian Cancer 3
Social Anxiety Disorder 3
Panic Disorder 3
Generalized Anxiety Disorder 3
Anxiety Disorders 3
Pancreatic Cancer 3
Lung Cancer 3

What is open in the Georgetown University pipeline

34 recruiting of 227 indexed (15% open); 130 completed (57%).

Phase mix: 27 late (III/IV) vs 98 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Georgetown University: open-pipeline peers nationwide

Peers matched on 227 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 5%10%15%20% Total trials Recruiting share Georgetown UniversityUniversity of IowaUniversity Hospitals Cleveland Medical CenterBrown UniversityNational Eye Institute (NEI)Arizona State University59th Medical WingAlliance Foundation TrialsHoag Memorial Hospital Presbyterian
Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 227 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Georgetown University page

227 registered trials is a research-attention snapshot, not an endorsement of Georgetown University or any single study.

  • 34 of Georgetown University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Georgetown University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Georgetown University pipeline card: 227 registered trials from official public datasets.Report a data error.